Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Citius Pharmaceuticals Inc Is A Biopharmaceutical Company Dedicated To The Development And Commercialization Of First-In-Class Critical Care Products, With A Focus On Oncology, Anti-Infectives In Adjunct Cancer Care And Distinct Prescription Products. It Aims To Provide Therapeutic Products That Address Unmet Medical Needs Yet Have A Lower Development Risk Than Is Usually Associated With New Chemical Entities. The Company'S Flagship Product Candidate Is Lymphir, An Engineered Il-2 Diphtheria Toxin Fusion Protein. It Operates Through A Single Operating And Reportable Segment Which Is Focused On Developing And Commercializing Pioneering Targeted Oncology Therapies.